Quest Partners LLC Akero Therapeutics, Inc. Transaction History
Quest Partners LLC
- $1.12 Trillion
- Q3 2024
A detailed history of Quest Partners LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 25 shares of AKRO stock, worth $882. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25
Previous 12,609
99.8%
Holding current value
$882
Previous $296 Million
99.76%
% of portfolio
0.0%
Previous 0.04%
Shares
4 transactions
Others Institutions Holding AKRO
# of Institutions
172Shares Held
72.7MCall Options Held
178KPut Options Held
164K-
Janus Henderson Group PLC London, X06.88MShares$243 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$197 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$192 Million2.13% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$185 Million3.88% of portfolio
-
Wellington Management Group LLP Boston, MA5.11MShares$180 Million0.02% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.64B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...